Alpha Teknova, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TKNO research report →
Range $7 – $9
Price Chart
About the company
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions.
- CEO
- Stephen Gunstream
- IPO
- 2021
- Employees
- 158
- HQ
- Hollister, CA, US
Get TickerSpark's AI analysis on TKNO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $479.95M
- P/E
- -25.86
- PEG
- -2.03
- P/S
- 10.45
- P/B
- 6.85
- EV/EBITDA
- -48.89
- Div Yield
- 0.00%
- Gross Margin
- 35.80%
- Op Margin
- -32.65%
- Net Margin
- -34.76%
- ROE
- -24.95%
- ROIC
- -17.10%
Latest fiscal year · YoY change
- Revenue
- $40.52M+7.4%
- Gross Profit
- $13.44M+85.9%
- Op Income
- $-16,976,000
- Net Income
- $-17,259,000+35.5%
- EPS
- $-0.32+43.9%
- OCF Growth
- +30.2%
- FCF Growth
- +27.5%
- 52W High
- $9.48
- 52W Low
- $1.91
- 50D MA
- $7.94
- 200D MA
- $5.26
- Beta
- 0.73
- RSI (14)
- 48
- Avg Volume
- 437.31K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Teknova posted a record quarter with 22% revenue growth, improved gross margin, and raised full-year guidance as biopharma demand and custom product momentum accelerated.· November 4, 2026
- Revenue hit a new quarterly record and rose 22% year over year, led by custom products.
- Clinical Solutions revenue jumped 86% year over year, while Lab Essentials grew 9%.
- Gross margin improved to 38.0% from 30.7% last year, helped by higher revenue and inventory-related absorption benefits.
- Management saw an early but broad-based pickup in biopharma demand tied to stronger biotech funding, especially in later-stage programs.
- The company raised 2026 revenue guidance and said it expects continued strength into Q4 and 2027.
Total revenue increased 22% year over year in the third quarter of 2026, reaching the highest quarterly revenue in company history. Lab Essentials revenue was $9 million, up from $8.3 million, and Clinical Solutions revenue was $3.2 million, up from $1.7 million. Gross profit was $4.8 million versus $3.2 million last year, and gross margin expanded to 38.0% from 30.7%. Net loss improved to $3.5 million, or negative $0.06 per diluted share, from $4.3 million, or negative $0.08 per diluted share; adjusted EBITDA was negative $1.0 million versus negative $1.6 million. Cash, cash equivalents and short-term investments were $16.6 million at quarter-end, with $13.2 million of total borrowings. In mid-October, the company completed a $46 million equity capital raise with net proceeds of approximately $43 million. Management raised 2026 total revenue guidance to $46 million to $48 million, expects gross margin in the mid-to-upper 30s for full-year 2026, forecasts fourth-quarter operating expenses of at least $8 million, and continues to expect free cash outflow of less than $8 million for 2026. The company said it will provide 2027 revenue guidance when it reports full-year 2026 results.
Stephen Gunstream framed the quarter as evidence that Teknova’s growth strategy is working, pointing to broad-based strength in custom products and early signs that improving biotech funding is translating into orders from biopharma customers. He emphasized that demand is coming from later-stage programs, diagnostics, and tools customers, while small and mid-sized biotech discovery spending remains soft. His tone was confident but measured, repeatedly noting that the recovery is early and that management wants to see a couple more quarters before declaring it durable.
Matt Lowell highlighted the financial leverage in the model: gross margin reached 38.0% versus 30.7% a year ago, operating expenses were $8.0 million, and free cash outflow improved to $1.4 million from $2.4 million. He said the company is raising 2026 revenue guidance to $46 million to $48 million and still expects full-year gross margin in the mid-to-upper 30s, with Q4 operating expenses of at least $8 million. He also explained that the mid-October $46 million equity raise was done to strengthen the balance sheet, improve the net cash position, and enhance flexibility for tuck-in acquisitions, not because the company needed capital to reach cash flow positivity.
Analysts focused on whether the biopharma funding recovery is durable, how much of the Clinical Solutions strength is tied to larger versus smaller customers, and whether the company is seeing early-stage spending return. Management said the momentum is broad across modalities but still early, with later-stage programs and specialty CDMOs leading the recovery, while discovery spending at small and midsized biotech companies remains weak. Questions also centered on M&A and the new capital raise; management said it has a long-standing target list but will remain disciplined on valuation and integration risk, and prefers tuck-ins or adjacent manufacturing capabilities such as proteins, enzymes, antibodies, cytokines, and growth factors. Build-Tek and Fill-Tek were described as early but promising funnel and scale-up tools, with revenue impact expected to build over the next couple of quarters rather than immediately.
The bullish case is that Teknova is seeing record revenue, margin expansion, and an early biopharma rebound at the same time. Management believes stronger biotech funding is starting to show up in custom orders, while Build-Tek and Fill-Tek could deepen customer relationships and expand the funnel over time.
The main risks are that management still considers the funding-driven recovery early and has not yet seen small and mid-sized biotech discovery spending return. The catalog business for some biopharma end markets remains pressured, and management said growth could stay lumpy because Clinical Solutions is inherently quarter-to-quarter volatile.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 20.4%
- Shares Outstanding
- 62.90M
- Float Shares
- 12.80M
of shares held by institutions
82 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for TKNO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Richard BlumenthalSenate · CT | Sell | Jul 29, 26 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Aug 3, 26 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Jul 30, 26 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Aug 11, 26 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Aug 4, 26 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Jul 23, 26 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Aug 3, 26 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Aug 7, 26 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Aug 10, 26 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Aug 3, 26 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Aug 6, 26 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Jul 20, 26 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Jul 20, 26 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Aug 3, 26 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 1.63M | ▲ 18.77K |
| Royce & Associates LP | 1.58M | ▼ 80.38K |
| Blackrock, Inc. | 796.78K | ▼ 83.00K |
| Roubaix Capital, LLC | 673.81K | ▼ 905.60K |
| Vanguard Group Inc | 593.10K | ▼ 32.45K |
| Ubs Group AG | 444.63K | ▼ 187.33K |
| Arrowstreet Capital, Limited Partnership | 366.76K | ▲ 366.76K |
| Bank Of America Corp | 366.42K | ▲ 110.66K |
| Geode Capital Management, LLC | 314.59K | ▲ 2.77K |
| Conestoga Capital Advisors, LLC | 314.55K | 0 |
| Silvercrest Asset Management Group LLC | 249.41K | ▲ 249.41K |
| Squarepoint Ops LLC | 220.30K | ▲ 184.35K |
Held by 115 ETFs
Biggest fund positions in TKNO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 14, 26 | DEMSKI MARTHA J | other | 12,000 |
| Jul 14, 26 | DEMSKI MARTHA J | other | 12,000 |
| Jun 1, 26 | Vos Alexander | other | 55,000 |
| Jun 1, 26 | ROBERTSON BRETT | other | 55,000 |
| Jun 1, 26 | DEMSKI MARTHA J | other | 55,000 |
| Feb 15, 26 | Terrill Damon | other | 148,000 |
| Feb 15, 26 | Lowell Matthew | other | 171,000 |
| Mar 6, 26 | Lowell Matthew | buy | 40,000 |
| Feb 15, 26 | Gunstream Stephen | other | 429,000 |
| Mar 6, 26 | Gunstream Stephen | buy | 26,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TKNO coverage
Recent articles, reports, and earnings notes.
No research on TKNO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TKNO report →Wall Street Analysts Think Alpha Teknova (TKNO) Could Surge 26.41%: Read This Before Placing a Bet
zacks.com · Nov 18
Alpha Teknova (NASDAQ:TKNO) versus Charles River Laboratories International (NYSE:CRL) Critical Analysis
defenseworld.net · Nov 14
Alpha Teknova, Inc. (NASDAQ:TKNO) Stock Has Consensus Price Target of $8.75 According to Analysts
defenseworld.net · Nov 6
Alpha Teknova Q3 Earnings Call Highlights
marketbeat.com · Nov 5
Alpha Teknova, Inc. (TKNO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Alpha Teknova (TKNO) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 4
Teknova Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 4
Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells
seekingalpha.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.